A composition capable of improving cognitive fatigue and use thereof

Abstract

The present application relates to a kind of composition capable of improving cognitive fatigue and its application.The composition includes ginsenoside, ergothioneine, pyrroloquinoline quinone, eucommia extract and schisandra extract.The composition related to the present application can improve cognitive fatigue from multiple dimensions, and test shows that the cognitive ability, motor ability and reaction ability of mental fatigue zebra fish can be significantly improved.

Description

Technical Field

[0001] This invention belongs to the field of pharmaceutical or food technology, and specifically relates to a composition that can improve cognitive fatigue and its application. Background Technology

[0002] Cognitive fatigue refers to a physiological state of decreased attention and efficiency caused by prolonged high-intensity cognitive activities. It manifests as poor concentration, decreased memory, sluggish thinking ("brain fog"), and reduced learning efficiency. It is one of the core symptoms of fatigue syndrome that seriously affects the quality of work and life. Its core pathology includes: (1) Brain tissue consumes about 20% of the body's energy, and insufficient mitochondrial function of neurons leads to a shortage of ATP supply in the cognitive center; (2) Decreased dopamine / norepinephrine levels in the prefrontal cortex and hippocampus affect attention and working memory; (3) Insufficient synthesis of neurotrophic factors (such as NGF and BDNF) leads to reduced synaptic plasticity, affecting memory encoding; (4) Neuroinflammation and oxidative stress damage cognitive-related neural circuits.

[0003] CN1913907A discloses a ginkgo phosphatidylserine complex for enhancing cognitive function and relieving mental fatigue, namely improving related factors such as increasing the speed and quality of memory, increasing the accuracy and attention of normal healthy individuals, preventing the decline in the speed and quality of memory in people with cognitive decline, and combating cognitive fatigue; it can also affect mood, especially the mood of healthy children, young people, middle-aged people and / or the elderly.

[0004] CN119817809A discloses a composition beneficial for improving brain cognition, memory, and sleep, and for preventing and improving Alzheimer's disease. This composition contains L-α-glycerophosphate choline (GPC), phosphatidylserine (PS), docosahexaenoic acid (DHA), tea theanine (L-theanine), B vitamins, and vitamin D3, and is prepared using existing technologies as a health product, dietary supplement, functional food, medical food, or nutritional supplement. It effectively nourishes nerve cells, enhances brain sensitivity, and improves cognitive function.

[0005] Existing "brain-boosting" products are mostly ginkgo biloba (which improves cerebral blood flow but does not address neuronal energy and neurotrophic issues) or DHA (structural nutrition but not functional intervention), lacking solutions to improve cognitive fatigue from multiple dimensions such as neuronal energy, neurotrophic factors, neurotransmitters, and antioxidant protection.

[0006] Therefore, developing a composition that can fundamentally alleviate cognitive fatigue and improve cognitive ability from multiple dimensions has become one of the urgent technical problems to be solved. Summary of the Invention

[0007] In view of the shortcomings of the prior art, the purpose of this invention is to provide a composition that can improve cognitive fatigue and its application.

[0008] To achieve this objective, the present invention adopts the following technical solution: In a first aspect, the present invention provides a composition capable of improving cognitive fatigue, the composition comprising: ginsenosides, ergothionein, pyrrolizinone (PQQ), Eucommia ulmoides extract and Schisandra chinensis extract.

[0009] In this invention, ginsenosides help maintain the plasticity of hippocampal synapses; ergothionein can specifically scavenge hydroxyl radicals and peroxynitrites in hippocampal and prefrontal neurons, protecting cognitively related synapses, while simultaneously regenerating NAD through the H2S / cGPDH pathway. + PQQ can restore neuronal energy metabolism; it can stimulate Schwann cells and astrocytes to synthesize nerve growth factor (NGF), which promotes the survival of cholinergic neurons and synaptic plasticity, and improves short-term memory and sustained attention; Eucommia ulmoides extract can enhance the brain tissue's antioxidant defense, improve learning and memory abilities, and protect the morphological integrity of neurons in the CA1 area of ​​the hippocampus; Schisandra chinensis extract can enhance learning and memory by inhibiting acetylcholinesterase and increasing the concentration of acetylcholine in the synaptic cleft, and protect hippocampal neurons against oxidative stress.

[0010] This invention creatively discovers that ginsenosides, ergothionein, pyrrolizinone, Eucommia ulmoides extract, and Schisandra chinensis extract work together to have a significant synergistic effect in improving cognitive fatigue.

[0011] Preferably, the composition comprises, by weight parts: 1-30 parts of ginsenoside, 5-100 parts of ergothionein, 1-50 parts of pyrroloquinoline quinone, 10-300 parts of Eucommia ulmoides extract and 10-100 parts of Schisandra chinensis extract.

[0012] Among them, the specific point values ​​for 1-30 portions can be 1 portion, 5 portions, 10 portions, 15 portions, 20 portions, 25 portions, 30 portions, etc.; the specific point values ​​for 5-100 portions can be 5 portions, 20 portions, 35 portions, 50 portions, 65 portions, 80 portions, 90 portions, 100 portions, etc.; the specific point values ​​for 1-50 portions can be 1 portion, 10 portions, 20 portions, 30 portions, 40 portions, 50 portions, etc.; and the specific point values ​​for 10-300 portions can be 10 portions, 50 portions, 100 portions, 150 portions, 200 portions, 250 portions, 300 portions, etc.

[0013] Preferably, the ginsenosides include ginsenoside CK.

[0014] Ginsenoside CK is derived from the dried root of ginseng (Panax ginseng), a plant belonging to the Araliaceae family. It is the main metabolite and final absorption form of diol-type ginsenosides in the human intestine. This invention creatively discovers that, compared to ginsenoside Rb1 and others, ginsenoside CK can better exert its synergistic effect with the aforementioned components, thereby improving the overall cognitive fatigue relief effect of the composition.

[0015] Preferably, the Eucommia ulmoides extract is prepared by a method comprising the following steps: Eucommia ulmoides raw material is mixed with a solution containing a eutectic solvent and subjected to hot extraction to obtain Eucommia ulmoides extract.

[0016] In this invention, the hot extraction of Eucommia ulmoides raw material using a solution containing a eutectic solvent can better increase the content of active ingredients in Eucommia ulmoides.

[0017] Preferably, the Eucommia ulmoides raw material includes Eucommia ulmoides leaf raw material and Eucommia ulmoides root raw material.

[0018] This invention creatively discovers that, in the preparation process of the extract, co-extracting Eucommia ulmoides leaves and roots can enrich the active ingredients to a greater extent compared to extracting either Eucommia ulmoides leaves or roots alone, resulting in an extract with a superior effect in relieving cognitive fatigue.

[0019] Preferably, the mass ratio of Eucommia ulmoides leaf raw material to Eucommia ulmoides root raw material is 5:1-10:1, for example, it can be 5:1, 6:1, 7:1, 8:1, 9:1, 10:1, etc.

[0020] Preferably, the raw materials for preparing the solution containing the eutectic solvent include the eutectic solvent and water.

[0021] Preferably, the eutectic solvent is obtained by reacting phenylalanine and lactic acid.

[0022] In this invention, phenylalanine acts as a hydrogen bond acceptor and lactic acid acts as a hydrogen bond donor. The eutectic solvent formed by the reaction can better achieve the extraction effect of the active ingredients in Eucommia ulmoides.

[0023] Preferably, the molar ratio of phenylalanine to lactic acid is 3:1-5:1, for example, it can be 3:1, 3.5:1, 4:1, 4.5:1, or 5:1; Preferably, the solution containing the eutectic solvent is prepared by a method comprising the following steps: Phenylalanine and lactic acid are mixed and reacted at 70-90℃ for 1-5 h. After cooling to 20-40℃, they are mixed with water to obtain a solution containing a eutectic solvent. Among them, the specific point values ​​in 70-90℃ can be 70℃, 75℃, 80℃, 85℃, 90℃, etc.; the specific point values ​​in 1-5 h can be 1 h, 2 h, 5 h, 4 h, 5 h, etc.; and the specific point values ​​in 20-40℃ can be 20℃, 25℃, 30℃, 35℃, 40℃, etc.

[0024] Preferably, the mass ratio of the eutectic solvent to water is 1:1 to 5:1, for example, it can be 1:1, 2:1, 3:1, 4:1, 5:1, etc.

[0025] Preferably, the ratio of the Eucommia ulmoides raw material to the solution containing the eutectic solvent is 1:5-1:10 g / mL, for example, it can be 1:5 g / mL, 1:6 g / mL, 1:7 g / mL, 1:8 g / mL, 1:9 g / mL, 1:10 g / mL, etc.

[0026] Preferably, the hot extraction temperature is 50-65℃ and the hot extraction time is 0.5-2 h.

[0027] Among them, the specific point values ​​in 50-65℃ can be 50℃, 55℃, 60℃, 65℃, etc., and the specific point values ​​in 0.5-2 h can be 0.5 h, 1 h, 1.5 h, 2 h, etc.

[0028] Preferably, the Schisandra chinensis extract is prepared by a method comprising the following steps: Schisandra chinensis raw material was mixed with water and subjected to hot extraction to obtain Schisandra chinensis extract.

[0029] Preferably, the ratio of Schisandra chinensis raw material to water is 1:5-1:10 g / mL, for example, it can be 1:5 g / mL, 1:6 g / mL, 1:7 g / mL, 1:8 g / mL, 1:9 g / mL, 1:10 g / mL, etc.

[0030] Preferably, the hot extraction temperature is 50-65℃ and the hot extraction time is 0.5-2 h.

[0031] Among them, the specific point values ​​in 50-65℃ can be 50℃, 55℃, 60℃, 65℃, etc., and the specific point values ​​in 0.5-2 h can be 0.5 h, 1 h, 1.5 h, 2 h, etc.

[0032] In a second aspect, the present invention provides the use of the composition described in the first aspect in the preparation of a medicine or food that can improve cognitive fatigue or enhance attention.

[0033] Compared with the prior art, the present invention has the following beneficial effects: The composition involved in this invention includes ginsenosides, ergothioneine, pyrrolizidine quinoline quinone, Eucommia ulmoides extract, and Schisandra chinensis extract. These components work synergistically to improve cognitive fatigue from multiple dimensions, exhibiting a significant synergistic effect in enhancing cognitive function.

[0034] Furthermore, compared to other ginsenosides such as Rb1, ginsenoside CK can better exert a synergistic effect with the above components, thereby improving the overall cognitive fatigue relief effect of the composition.

[0035] Furthermore, in the preparation of Eucommia ulmoides extract, hot extraction of Eucommia ulmoides raw materials using a solution containing a eutectic solvent can better improve the content of active ingredients in Eucommia ulmoides; and using phenylalanine as a hydrogen bond acceptor and lactic acid as a hydrogen bond donor, the eutectic solvent formed by the reaction can better achieve the extraction effect of active ingredients in Eucommia ulmoides; in addition, co-extraction of Eucommia ulmoides leaves and roots, compared with single Eucommia ulmoides leaf extract or Eucommia ulmoides root extract, can enrich the active ingredients to a greater extent, and the resulting extract has a better cognitive fatigue relief effect. Attached Figure Description

[0036] Figure 1 This is a comparison chart of the proportion of blue areas in the cross maze of zebrafish from different experimental groups in Test Example 1.

[0037] Figure 2 This is a comparison chart of the total distance traveled by zebrafish in different experimental groups in the cross maze in Test Example 1.

[0038] Figure 3 This is a comparison chart of the average reaction speed of zebrafish in different experimental groups under light and dark conditions in Test Example 1. Detailed Implementation

[0039] To further illustrate the technical means and effects of the present invention, the following describes the technical solution of the present invention in conjunction with preferred embodiments of the present invention. However, the present invention is not limited to the scope of the embodiments.

[0040] Preparation Example 1-1 This preparation example provides an Eucommia ulmoides extract, prepared by the following method: (1) Preparation of a solution containing a eutectic solvent: Phenylalanine and lactic acid were mixed in a molar ratio of 4:1 and reacted at 80°C for 2 h. After cooling to 30°C, they were mixed with water in a mass ratio of 3:1 to obtain a solution containing a eutectic solvent.

[0041] (2) The leaves of Eucommia ulmoides are pulverized to 100 mesh to obtain Eucommia ulmoides leaf powder, and the roots of Eucommia ulmoides are pulverized to 80 mesh to obtain Eucommia ulmoides root powder; the Eucommia ulmoides leaf powder and Eucommia ulmoides root powder are mixed at a mass ratio of 8:1 to obtain Eucommia ulmoides powder. Eucommia ulmoides powder was mixed with a solution containing a eutectic solvent at a ratio of 1:7 g / mL and subjected to hot extraction (extraction at 60℃ for 1 h) to obtain an extract. The extract was concentrated and freeze-dried to obtain Eucommia ulmoides extract.

[0042] Preparation Examples 1-2 This preparation example provides an Eucommia ulmoides extract, prepared by the following method: (1) Preparation of a solution containing a eutectic solvent: Phenylalanine and lactic acid were mixed in a molar ratio of 3:1 and reacted at 70°C for 4 h. After cooling to 20°C, they were mixed with water in a mass ratio of 1:1 to obtain a solution containing a eutectic solvent.

[0043] (2) The leaves of Eucommia ulmoides are pulverized to 100 mesh to obtain Eucommia ulmoides leaf powder, and the roots of Eucommia ulmoides are pulverized to 80 mesh to obtain Eucommia ulmoides root powder; the Eucommia ulmoides leaf powder and Eucommia ulmoides root powder are mixed at a mass ratio of 5:1 to obtain Eucommia ulmoides powder. Eucommia ulmoides powder was mixed with a solution containing a eutectic solvent at a ratio of 1:5 g / mL and subjected to hot extraction (extraction at 65℃ for 0.5 h) to obtain an extract. The extract was then concentrated and freeze-dried to obtain Eucommia ulmoides extract.

[0044] Preparation Examples 1-3 This preparation example provides an Eucommia ulmoides extract, prepared by the following method: (1) Preparation of a solution containing a eutectic solvent: Phenylalanine and lactic acid were mixed in a molar ratio of 5:1 and reacted at 90°C for 1 h. After cooling to 40°C, they were mixed with water in a mass ratio of 5:1 to obtain a solution containing a eutectic solvent.

[0045] (2) The leaves of Eucommia ulmoides are crushed to 100 mesh to obtain Eucommia ulmoides leaf powder, and the roots of Eucommia ulmoides are crushed to 80 mesh to obtain Eucommia ulmoides root powder; the Eucommia ulmoides leaf powder and Eucommia ulmoides root powder are mixed at a mass ratio of 10:1 to obtain Eucommia ulmoides powder. Eucommia ulmoides powder was mixed with a solution containing a eutectic solvent at a ratio of 1:10 g / mL and subjected to hot extraction (extraction at 50℃ for 2 h) to obtain an extract. The extract was concentrated and freeze-dried to obtain Eucommia ulmoides extract.

[0046] Preparation Examples 1-4 This preparation example provides an extract of Eucommia ulmoides, which differs from Preparation Example 1-1 only in that in step (1), phenylalanine is replaced with an equimolar amount of hydrogen bond acceptor L-carnitine, while the rest of the steps are consistent with Preparation Example 1-1.

[0047] Preparation Examples 1-5 This preparation example provides an extract of Eucommia ulmoides, which differs from Preparation Example 1-1 only in that in step (1), lactic acid is replaced with an equimolar amount of hydrogen bond donor oxalic acid, while the remaining steps are consistent with Preparation Example 1-1.

[0048] Preparation Examples 1-6 This preparation example provides an Eucommia ulmoides extract, which differs from Preparation Example 1-1 only in that the Eucommia ulmoides root powder is removed from the raw materials in step (2), and only the Eucommia ulmoides leaf powder is mixed with a solution containing a eutectic solvent for hot extraction. The remaining steps are consistent with Preparation Example 1-1 to obtain Eucommia ulmoides leaf extract.

[0049] Preparation Examples 1-7 This preparation example provides an Eucommia ulmoides extract, which differs from Preparation Example 1-1 only in that the Eucommia ulmoides leaf powder is removed from the raw materials in step (2), and only the Eucommia ulmoides root powder is mixed with a solution containing a eutectic solvent for hot extraction. The remaining steps are consistent with Preparation Example 1-1 to obtain Eucommia ulmoides root extract.

[0050] Preparation Example 2-1 This preparation example provides a Schisandra chinensis extract, prepared by the following method: Schisandra chinensis was dried and pulverized to 80 mesh to obtain Schisandra chinensis powder; Schisandra chinensis powder was mixed with water at a material-to-liquid ratio of 1:7 g / mL and subjected to hot extraction (extraction at 60℃ for 1 h) to obtain an extract; the extract was concentrated and freeze-dried to obtain Schisandra chinensis extract.

[0051] Preparation Example 2-2 This preparation example provides a Schisandra chinensis extract, prepared by the following method: Schisandra chinensis was dried and pulverized to 80 mesh to obtain Schisandra chinensis powder; the Schisandra chinensis powder was mixed with water at a material-to-liquid ratio of 1:5 g / mL and subjected to hot extraction (extraction at 50℃ for 2 h) to obtain an extract; the extract was concentrated and freeze-dried to obtain Schisandra chinensis extract.

[0052] Preparation Examples 2-3 This preparation example provides a Schisandra chinensis extract, prepared by the following method: Schisandra chinensis was dried and pulverized to 80 mesh to obtain Schisandra chinensis powder; the Schisandra chinensis powder was mixed with water at a material-to-liquid ratio of 1:10 g / mL and subjected to hot extraction (extraction at 65℃ for 0.5 h) to obtain an extract; the extract was concentrated and freeze-dried to obtain Schisandra chinensis extract.

[0053] Example 1 This embodiment provides a composition comprising, by weight parts: 20 parts of ginsenoside CK, 50 parts of ergothionein, 30 parts of pyrroloquinoline quinone, 100 parts of Eucommia ulmoides extract from Preparation Example 1-1, and 50 parts of Schisandra chinensis extract from Preparation Example 2-1.

[0054] Example 2 This embodiment provides a composition comprising, by weight parts: 30 parts of ginsenoside CK, 10 parts of ergothionein, 50 parts of pyrroloquinoline quinone, 10 parts of Eucommia ulmoides extract from Preparation Examples 1-2, and 100 parts of Schisandra chinensis extract from Preparation Examples 2-2.

[0055] Example 3 This embodiment provides a composition comprising, by weight parts: 5 parts of ginsenoside CK, 60 parts of ergothionein, 5 parts of pyrroloquinoline quinone, 100 parts of Eucommia ulmoides extract from Preparation Examples 1-3, and 10 parts of Schisandra chinensis extract from Preparation Examples 2-3.

[0056] Examples 4-7 Examples 4-7 each provide a composition, which differs from Example 1 only in that the Eucommia ulmoides extract of Preparation Example 1-1 is replaced with equal parts by mass of Eucommia ulmoides extract of Preparation Example 1-4-Preparation Example 1-7.

[0057] Example 8 This embodiment provides a composition that differs from Example 1 only in that ginsenoside CK is replaced with an equal mass of ginsenoside Rb1.

[0058] Comparative Example 1 This comparative example provides a composition comprising, by mass parts: 20 parts of ginsenoside CK, 50 parts of ergothionein, 30 parts of pyrroloquinoline quinone, and 100 parts of the Eucommia ulmoides extract of Preparation Example 1-1.

[0059] Comparative Example 2 This embodiment provides a composition comprising, by weight parts: 20 parts of ginsenoside CK, 50 parts of ergothionein, 30 parts of pyrroloquinoline quinone, and 50 parts of Schisandra chinensis extract from Preparation Example 2-1.

[0060] Comparative Example 3 This embodiment provides a composition comprising, by mass parts: 20 parts of ginsenoside CK, 50 parts of ergothioneine, 100 parts of Eucommia ulmoides extract from Preparation Example 1-1, and 50 parts of Schisandra chinensis extract from Preparation Example 2-1.

[0061] Comparative Example 4 This embodiment provides a composition comprising, by weight parts: 20 parts of ginsenoside CK, 30 parts of pyrroloquinoline quinone, 100 parts of Eucommia ulmoides extract from Preparation Example 1-1, and 50 parts of Schisandra chinensis extract from Preparation Example 2-1.

[0062] Comparative Example 5 This embodiment provides a composition comprising, by weight parts: 50 parts of ergothioneine, 30 parts of pyrroloquinoline quinone, 100 parts of Eucommia ulmoides extract from Preparation Example 1-1, and 50 parts of Schisandra chinensis extract from Preparation Example 2-1.

[0063] Test Example 1 Cognitive fatigue relief effect test: (1) Construction of a zebrafish mental fatigue model: Wild-type AB strain zebrafish were randomly selected 5 days after fertilization (5dpf) and placed in a behavior analyzer at a temperature maintained at 28.5℃. The program was set as follows: 100% white light for 20 s, 0% white light for 5 s, 100% white light for 15 s, 0% white light for 3 s, and strong light stimulation for 6 h to construct a zebrafish mental fatigue model.

[0064] (2) Trial grouping and intervention method: Wild-type AB strain zebrafish, 5 days post-fertilization (5 dpf), were randomly selected and placed in 6-well plates. They were randomly divided into 15 groups (including 1 control group, 1 model group, and 13 experimental groups), with 20 fish in each group. Different treatments were then administered. The specific grouping and treatments are as follows: Experimental group: Compositions from each example or comparative example were administered in water at a concentration of 0.1 g / mL in a six-well plate, with a volume of 3 mL per well. A zebrafish mental fatigue model was established by white light stroboscopic irradiation. The zebrafish were placed in a behavioral analyzer maintained at 28.5℃, with the following program: 100% white light for 20 s, 0% white light for 5 s, 100% white light for 15 s, 0% white light for 3 s, and strong light stimulation for 6 h. On the day the treatment ended, the zebrafish were rinsed three times with standard dilution water.

[0065] Model group: A zebrafish mental fatigue model was established by white light stroboscopic irradiation. The zebrafish were placed in a behavior analyzer with the temperature maintained at 28.5℃. The program was set as follows: 100% white light for 20 s, 0% white light for 5 s, 100% white light for 15 s, 0% white light for 3 s, strong light stimulation for 6 hours. On the day the treatment ended, the zebrafish were rinsed 3 times with standard dilution water.

[0066] Control group: Zebrafish were kept in a six-well plate for 6 hours (without white light strobe exposure), and then rinsed 3 times with standard diluted water.

[0067] (3) After the above intervention is completed, indicator testing will be conducted: (3.1) Ten zebrafish were randomly selected from each experimental group and placed in a behavior analyzer. Their proportion of the blue area and total movement distance in the cross maze (the cross maze mold was shaped like a cross, with four square areas representing blue, yellow, red, and green areas respectively; juvenile zebrafish selectively preferred blue among the four colors) were recorded to assess their cognitive and motor abilities. The results are as follows: Figure 1 and Figure 2 As shown.

[0068] Figure 1 In the diagram, *, **, and *** indicate p < 0.05, p < 0.01, and p < 0.001 compared to the model group, respectively; #, ##, and ### indicate p < 0.05, p < 0.01, and p < 0.001 compared to Example 1, respectively. Figure 2 In the text, *** indicates p < 0.001 compared to the model group, and #, ##, and ### indicate p < 0.05, p < 0.01, and p < 0.001 compared to Example 1, respectively.

[0069] (3.2) The remaining 10 fish from each experimental group were placed in a behavior analyzer. Five minutes of darkness, five minutes of light, five minutes of darkness, and five minutes of light were set. The average speed every 5 minutes was analyzed to assess reaction ability. The results are as follows: Figure 3 As shown ( Figure 3 In the text, *** indicates p < 0.001 compared to the model group, and ### indicates p < 0.001 compared to Example 1.

[0070] Depend on Figure 1-3 The data shows that the proportion of blue area, movement distance, and average speed of light-dark reaction in the model group of zebrafish were significantly reduced, indicating that the light flicker irradiation-induced mental fatigue model was successful. After intervention with the composition of this invention, the cognitive ability (proportion of blue area), movement ability (movement distance), and reaction ability (average speed of light-dark reaction) of zebrafish were significantly improved, indicating that the composition of this invention has a significant effect on improving mental fatigue.

[0071] A comparison of the data from Example 1 and Comparative Examples 1-5 shows that ginsenoside CK, ergothionein, pyrroloquinoline quinone, Eucommia ulmoides extract, and Schisandra chinensis extract, in combination, can significantly improve the cognitive, motor, and reaction abilities of zebrafish, and have a significant synergistic effect in improving cognition.

[0072] A comparison of the data from Examples 1 and 4-7 shows that, in the preparation of Eucommia ulmoides extract, using phenylalanine as a hydrogen bond acceptor and lactic acid as a hydrogen bond donor to form a eutectic solvent, and then using a solution containing the eutectic solvent for hot extraction of Eucommia ulmoides raw materials, can better increase the content of active ingredients in Eucommia ulmoides. In addition, co-extraction of Eucommia ulmoides leaves and roots, compared with single Eucommia ulmoides leaf extract or Eucommia ulmoides root extract, can enrich the active ingredients to a greater extent, and the resulting extract has a better cognitive fatigue relief effect.

[0073] A comparison of the data from Example 1 and Example 8 shows that ginsenoside CK, compared to other ginsenosides such as Rb1, can better exert a synergistic effect with the above components, improving the cognitive, motor, and reaction abilities of zebrafish.

[0074] The applicant declares that the technical solution of this invention is illustrated by the above embodiments, but this invention is not limited to the above embodiments, that is, it does not mean that this invention must rely on the above embodiments to be implemented. Those skilled in the art should understand that any improvements to this invention, equivalent substitutions of raw materials for the products of this invention, addition of auxiliary components, selection of specific methods, etc., all fall within the protection scope and disclosure scope of this invention.

[0075] The preferred embodiments of the present invention have been described in detail above. However, the present invention is not limited to the specific details in the above embodiments. Within the scope of the technical concept of the present invention, various simple modifications can be made to the technical solution of the present invention, and these simple modifications all fall within the protection scope of the present invention.

[0076] It should also be noted that the various specific technical features described in the above specific embodiments can be combined in any suitable manner without contradiction. In order to avoid unnecessary repetition, the present invention will not describe the various possible combinations separately.

Claims

1. A composition capable of improving cognitive fatigue, characterized in that, The composition includes: ginsenosides, ergothionein, pyrrolizinone, Eucommia ulmoides extract and Schisandra chinensis extract.

2. The composition according to claim 1, characterized in that, The composition comprises, by weight parts: 1-30 parts of ginsenosides, 5-100 parts of ergothionein, 1-50 parts of pyrroloquinoline quinone, 10-300 parts of Eucommia ulmoides extract and 10-100 parts of Schisandra chinensis extract.

3. The composition according to claim 1 or 2, characterized in that, The ginsenosides include ginsenoside CK.

4. The composition according to any one of claims 1-3, characterized in that, The Eucommia ulmoides extract was prepared using a method comprising the following steps: Eucommia ulmoides raw material is mixed with a solution containing a eutectic solvent and subjected to hot extraction to obtain Eucommia ulmoides extract.

5. The composition according to claim 4, characterized in that, The Eucommia ulmoides raw materials include Eucommia ulmoides leaf raw materials and Eucommia ulmoides root raw materials; Preferably, the mass ratio of Eucommia ulmoides leaf raw material to Eucommia ulmoides root raw material is 5:1-10:

1.

6. The composition according to claim 4 or 5, characterized in that, The raw materials for preparing the solution containing the eutectic solvent include the eutectic solvent and water; Preferably, the eutectic solvent is obtained by reacting phenylalanine and lactic acid; Preferably, the molar ratio of phenylalanine to lactic acid is 3:1-5:1; Preferably, the solution containing the eutectic solvent is prepared by a method comprising the following steps: Phenylalanine and lactic acid are mixed and reacted at 70-90℃ for 1-5 h. After cooling to 20-40℃, they are mixed with water to obtain a solution containing a eutectic solvent. Preferably, the mass ratio of the eutectic solvent to water is 1:1 to 5:1; Preferably, the ratio of the Eucommia ulmoides raw material to the solution containing a eutectic solvent is 1:5-1:10 g / mL.

7. The composition according to any one of claims 4-6, characterized in that, The hot extraction temperature is 50-65℃, and the hot extraction time is 0.5-2 h.

8. The composition according to any one of claims 1-7, characterized in that, The Schisandra chinensis extract was prepared using a method comprising the following steps: Schisandra chinensis raw material was mixed with water and subjected to hot extraction to obtain Schisandra chinensis extract.

9. The composition according to claim 8, characterized in that, The ratio of Schisandra chinensis raw material to water is 1:5-1:10 g / mL; Preferably, the hot extraction temperature is 50-65℃ and the hot extraction time is 0.5-2 h.

10. Use of the composition of any one of claims 1-9 in the preparation of a pharmaceutical or food product capable of improving cognitive fatigue.

Images